ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 42 | November 1, 1985

Download PDF Visit The Full Archive

Related Articles

Iressa Just As Effective As Chemotherapy For Second-Line Therapy, Study Finds

November 28, 2008

ASCO: NCI Director Should Be A Clinician; NBCC Endorses Mary-Claire King

March 10, 1995

Interview with Christine Berg: ST Findings Relevant Only To High-Risk;

November 26, 2010

Cooperative group Outreach Extended Three ears, Gets Extra $1 Million, Up to Four More Awards

October 28, 1983

Melanoma Vaccine Near Phase 3, Other Studies Discussed At ACS Seminar

April 13, 1990

Dasatinib, Nilotinib Show Strong Early Results As Frontline Therapy For CML

December 28, 2007